報價延遲最少15分鐘:2024/05/16 03:01 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
42.31 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.73/-2.48
|
|
企業價值
8.06B
|
| 資產負債 |
|
每股賬面淨值
3.10
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/16 03:01 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions. |